Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
John W. Funder, Robert M. Carey, Carlos Fardella, Celso E. Gomez-Sanchez, Franco Mantero, Michael Stowasser, William F. Young Jr., and Victor M. Montori*
Prince Henry’s Institute of Medical Research (J.W.F.), Clayton VIC 3168, Australia; University of Virginia Health System (R.M.C.), Charlottesville, Virginia 22908; Facultad de Medicina Pontificia Universidad Católica de Chile (C.F.), Santiago 1365, Chile; G.V. (Sonny) Montgomery VA Medical Center (C.E.G .- S.), Jackson, Mississippi 39216; University of Padova (F.M.), 35100 Padua, Italy; University of Queensland (M.S.), Brisbane QLD 4000, Australia; and Mayo Clinic (W.F.Y., V.M.M.), Rochester, Minnesota 55902
Objective: Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism.
Participants: The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, six additional experts, one methodologist, and a medical writer. The Task Force received no corporate funding or remuneration.
Evidence: Systematic reviews of available evidence were used to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Develop- ment, and Evaluation (GRADE) group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations.
Consensus Process: Consensus was guided by systematic reviews of evidence and discussions during one group meeting, several conference calls, and multiple e-mail communications. The drafts prepared by the task force with the help of a medical writer were reviewed successively by The Endocrine Society’s CGS, Clinical Affairs Core Committee (CACC), and Council. The version approved by the CGS and CACC was placed on The Endocrine Society’s Web site for comments by members. At each stage of review, the Task Force received written comments and incorporated needed changes.
Conclusions: We recommend case detection of primary aldosteronism be sought in higher risk groups of hypertensive patients and those with hypokalemia by determining the aldosterone-renin ratio under standard conditions and that the condition be confirmed/excluded by one of four commonly used con- firmatory tests. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recom- mend the presence of a unilateral form of primary aldosteronism should be established/excluded by bilateral adrenal venous sampling by an experienced radiologist and, where present, optimally treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia, or those unsuitable for surgery, optimally be treated medically by mineralocorticoid receptor antagonists. (J Clin Endocrinol Metab 93: 3266-3281, 2008)
Summary of Recommendations
1.0 Case detection
1.1 We recommend the case detection of primary aldosteron- ism (PA) in patient groups with relatively high prevalence of PA.
(110000) These include patients with Joint National Commis- sion stage 2 (>160-179/100-109 mm Hg), stage 3 (>180/110 mm Hg), or drug-resistant hypertension; hypertension and spon- taneous or diuretic-induced hypokalemia; hypertension with ad- renal incidentaloma; or hypertension and a family history of
* Evidence-based reviews for this guideline were prepared under contract with The En- docrine Society.
Abbreviations: ARR, Aldosterone to renin ratio; APA, aldosterone-producing adenoma; AVS, adrenal venous sampling; CT, computed tomography; DRC, direct renin concentra- tion; FH-I, familial hyperaldosteronism type I; FST, fludrocortisone suppression testing; GRA, glucocorticoid-remediable aldosteronism; IHA, idiopathic hyperaldosteronism; IVC, inferior vena cava; MR, mineralocorticoid receptor; PA, primary aldosteronism; PAC, plasma aldosterone concentration; PRA, plasma renin activity; SIT, sodium infusion test; UAH, unilateral adrenal hyperplasia.
early-onset hypertension or cerebrovascular accident at a young age (<40 yr). We also recommend case detection for all hyper- tensive first-degree relatives of patients with PA. (1|0000)
1.2 We recommend use of the plasma aldosterone to renin ratio (ARR) to detect cases of PA in these patient groups. (110000)
2.0 Case confirmation
2.1 Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo test- ing, by any of four confirmatory tests, to definitively confirm or exclude the diagnosis. (110000)
3.0 Subtype classification
3.1 We recommend that all patients with PA undergo an ad- renal computed tomography (CT) scan as the initial study in subtype testing and to exclude large masses that may represent adrenocortical carcinoma. (11+000)
3.2 We recommend that, when surgical treatment is practi- cable and desired by the patient, the distinction between unilat- eral and bilateral adrenal disease be made by adrenal venous sampling (AVS) by an experienced radiologist. (110000)
3.3 In patients with onset of confirmed PA earlier than at 20 yr of age and in those who have a family history of PA or of strokes at young age (<40 yr), we suggest genetic testing for glucocorticoid-remediable aldosteronism (GRA). (21+000)
4.0 Treatment
4.1 We recommend that treatment by unilateral laparoscopic adrenalectomy be offered to patients with documented unilateral PA [i.e. aldosterone-producing adenoma (APA) or unilateral adre- nal hyperplasia (UAH)]. (110000) If a patient is unable or unwill- ing to undergo surgery, we recommend medical treatment with a mineralocorticoid receptor (MR) antagonist. (1|֏֏00)
4.2 In patients with PA due to bilateral adrenal disease, we rec- ommend medical treatment with an MR antagonist (1|++00); we suggest spironolactone as the primary agent with eplerenone as an alternative. (2|+000)
4.3 In patients with GRA, we recommend the use of the lowest dose of glucocorticoid that can normalize blood pres- sure and serum potassium levels rather than first-line treat- ment with an MR antagonist. (110000)
Method of Development of Evidence-Based Guidelines
T he Clinical Guidelines Subcommittee of The Endocrine So- ciety deemed detection, diagnosis, and treatment of pa- tients with PA a priority area in need of practice guidelines and appointed a seven-member Task Force to formulate evidence- based recommendations. The Task Force followed the approach recommended by the Grading of Recommendations, Assess- ment, Development, and Evaluation (GRADE) group, an inter- national group with expertise in development and implementa- tion of evidence-based guidelines (1).
The Task Force used the best available research evidence that members identified to inform the recommendations and consis-
tent language and graphical descriptions of both the strength of a recommendation and the quality of evidence. In terms of the strength of the recommendation, strong recommendations use the phrase “we recommend” and the number 1, and weak rec- ommendations use the phrase “we suggest” and the number 2. Cross-filled circles indicate the quality of the evidence, such that ĐOOO denotes very low quality evidence; +000, low quality; 9000, moderate quality; and 000, high quality. The Task Force has confidence that patients who receive care according to the strong recommendations will derive, on average, more good than harm. Weak recommendations require more careful con- sideration of the patient’s circumstances, values, and preferences to determine the best course of action. A detailed description of this grading scheme has been published elsewhere (2).
Linked to each recommendation is a description of the evi- dence, values that panelists considered in making the recommen- dation (when making these explicit was necessary), and remarks, a section in which panelists offer technical suggestions for testing conditions, dosing, and monitoring. These technical comments reflect the best available evidence applied to a typical patient. Often, this evidence comes from the unsystematic observations of the panelists and should, therefore, be considered suggestions.
Definition and Clinical Significance of PA
What is PA?
PA is a group of disorders in which aldosterone production is inappropriately high, relatively autonomous from the renin-an- giotensin system, and nonsuppressible by sodium loading. Such inappropriate production of aldosterone causes cardiovascular damage, suppression of plasma renin, hypertension, sodium re- tention, and potassium excretion that if prolonged and severe may lead to hypokalemia. PA is commonly caused by an adrenal adenoma, by unilateral or bilateral adrenal hyperplasia, or in rare cases by the inherited condition of GRA.
How common is PA?
Most experts previously described PA in less than 1% of pa- tients with mild-to-moderate essential hypertension and had as- sumed hypokalemia was a sine qua non for diagnosis (3-9). Accumulating evidence has challenged these assumptions. Cross-sectional and prospective studies report PA in more than 10% of hypertensive patients, both in general and in specialty settings (10-18).
How frequent is hypokalemia in PA?
In recent studies, only a minority of patients with PA (9- 37%) had hypokalemia (19). Thus, normokalemic hypertension constitutes the most common presentation of the disease, with hypokalemia probably present in only the more severe cases. Half the patients with an APA and 17% of those with idiopathic hyperaldosteronism (IHA) had serum potassium concentrations less than 3.5 mmol/liter (17, 20). Thus, the presence of hypoka- lemia has low sensitivity and specificity and a low positive pre- dictive value for the diagnosis of PA.
Why is PA important?
This condition is important not only because of its prevalence but also because PA patients have higher cardiovascular mor- bidity and mortality than age- and sex-matched patients with essential hypertension and the same degree of blood pressure elevation (21,22). Furthermore, specific treatments are available that ameliorate the impact of this condition on patient-important outcomes.
1.0 Case Detection
1.1 We recommend the case detection of PA in patient groups with relatively high prevalence of PA (listed in Table 1) (Fig. 1). (110000) These include patients with Joint National Commis- sion stage 2 (>160-179/100-109 mm Hg), stage 3 (>180/110 mm Hg), or drug-resistant hypertension; hypertension and spon- taneous or diuretic-induced hypokalemia; hypertension with ad- renal incidentaloma; or hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (<40 yr). We also recommend case detection for all hyper- tensive first-degree relatives of patients with PA. (110000)
1.1 Evidence
Indirect evidence links the detection of PA with improved patient outcomes. There are no clinical trials of screening that measure the impact of this practice on morbidity, mortality, or quality-of-life outcomes. Patients could potentially be harmed by the work-up and treatment (i.e. by withdrawal of antihyperten- sive medication, invasive vascular examination, or adrenalec- tomy) aimed at vascular protection along with easier and better blood pressure control. There is strong evidence linking im- proved blood pressure control and reduction in aldosterone lev- els to improved cardiac and cerebrovascular outcomes (38). Un- til prospective studies inform us differently, we recommend that
all hypertensive first-degree relatives of patients with PA undergo ARR testing.
1.1 Values
Our recommendation to detect cases of PA places a high value on avoiding the risks associated with missing the diagnosis (and thus forgoing the opportunity of a surgical cure or improved control of hypertension through specific medical treatment) and a lower value on avoiding the risk of falsely classifying a hyper- tensive patient as having PA and exposing him or her to addi- tional diagnostic testing.
1.2 We recommend use of the plasma ARR to detect cases of PA in these patient groups (Fig. 1). (110000)
1.2 Evidence
The ARR is currently the most reliable available means of screening for PA. Although valid estimates of test characteristics of the ARR are lacking (mainly due to limitations in the design of studies that have addressed this issue) (39), numerous studies have demonstrated the ARR to be superior to measurement of potassium or aldosterone (both of which have lower sensitivity) or of renin (which is less specific) in isolation (40-42).
Like all biochemical case detection tests, the ARR is not with- out false positives and negatives (17, 18, 39, 43-45). Table 2 documents the effect of medications and conditions on the ARR. The ARR should therefore be regarded as a detection test only and should be repeated if the initial results are inconclusive or difficult to interpret because of suboptimal sampling conditions (e.g. maintenance of some medications listed in Table 2).
1.2 Values
Similar values underpin our recommendation to target sub- jects in groups with documented high prevalence of PA and to test them by ARR. In particular, this recommendation acknowl- edges the costs currently associated with ARR testing of all pa-
| Patient group | Prevalence |
|---|---|
| Moderate/severe hypertension. The prevalence rates cited here are from Mosso et al. (16). Others have reported similar estimates (18, 23-25). The classification of blood pressure for adults (aged 18 yr and older) was based on the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, which establishes three different stages: stage 1, SBP 140-159, DBP 90-99; stage 2, SBP 160-179, DBP 100-109; stage 3, SBP > 180, DBP > 110 (10). When SBP and DBP were in different categories, the higher category was selected to classify the individual's blood pressure status. | Overall, 6.1%; stage 1 (mild), 2%; stage 2 (moderate), 8%; stage 3 (severe), 13% 17-23% Specific prevalence figures are not available, but PA is more frequently found in this group. |
| Resistant hypertension, defined as SBP > 140 and DBP > 90 despite treatment with three hypertensive medications. The prevalence rates cited here are from Refs. 26-31. Hypertensive patients with spontaneous or diuretic-induced hypokalemia. | |
| Hypertension with adrenal incidentaloma (32-37), defined as an adrenal mass detected incidentally during imaging performed for extraadrenal reasons. | Median, 2% (range, 1.1-10%) One retrospective study that excluded patients with hypokalemia and severe hypertension found APA in 16 of 1004 subjects (37). |
Patients with hypertension that are at increased risk for PA
PA unlikely
-
Use ARR to detect cases 1| @@00
+
PA unlikely
-
Conduct confirmatory testing 1|0000
+
Adrenal CT (1)+ΦΟΟ)
If surgery desired
Subtype testing*
If surgery not desired
AVS (1 +ΦΦΟ)
Bilateral
Unilateral
Treat with MR antagonist (1|0000)
Treat with laparoscopic adrenalectomy (1|000)
tients with essential hypertension. Against this recommendation for selective testing, however, must be weighed the risk of missing or at least delaying the diagnosis of PA in some hypertensive individuals. The consequences of this may include the later de- velopment of more severe and resistant hypertension resulting from failure to lower levels of aldosterone or to block its actions. Furthermore, duration of hypertension has been reported by sev- eral investigators to be a negative predictor of outcome after unilateral adrenalectomy for APA (46, 47), suggesting that de- lays in diagnosis may result in a poorer response to specific treat- ment once PA is finally diagnosed.
1.2 Remarks: technical aspects required for the correct implementation of recommendation 1.2
Testing conditions (Tables 3 and 4)
The ARR is most sensitive when used in patients from whom samples are collected in the morning after patients have been out of bed for at least 2 h, usually after they have been seated for 5-15 min. Ideally, patients should have unrestricted dietary salt intake before testing. In many cases, the ARR can be confidently inter- preted with knowledge of the effect on the ARR of continued
medications or suboptimal conditions of testing, avoiding delay and allowing the patient to proceed directly to confirmatory/ exclusion testing. Washout of all interfering antihypertensive medications is feasible in patients with mild hypertension but is potentially problematic in others, and perhaps unnecessary in that medications with minimal effect on the ARR can be used in their place (Table 2).
Assay reliability
Although newer techniques are evolving, we prefer to use validated immunometric assays for plasma renin activity (PRA) or direct renin concentration (DRC); PRA takes into account factors (such as estrogen-containing preparations) that affect en- dogenous substrate levels. Laboratories should use aliquots from human plasma pools, carefully selected to cover the critical range of measurements, rather than the lyophilized controls provided by the manufacturer to monitor intra- and interassay reproduc- ibility and long-term stability. Because the ARR is mathemati- cally highly dependent on renin (49), renin assays should be sufficiently sensitive to measure levels as low as 0.2-0.3 ng/ml·h (DRC 2 mU/liter) (10, 16). For PRA, but not DRC, sensitivity for levels less than 1 ng/ml.h can be improved by prolonging the duration of the assay incubation phase as suggested by Sealey and Laragh (50). Although most laboratories use RIA for plasma and urinary aldosterone, measured levels of standards have been shown to be unacceptably different in some instances (51). Tan- dem mass spectrometry is increasingly used and has proved to be much more consistent in performance (52).
Interpretation
There are important and confusing differences between lab- oratories in the methods and units used to report values of renin and aldosterone. For aldosterone, 1 ng/dl converts to 27.7 pmol/ liter in Système International (SI) units. For immunometric meth- ods of directly measuring renin concentration, a PRA level of 1 ng/ml·h (12.8 pmol/liter·min in SI units) converts to a DRC of approximately 8.2 mU/liter (5.2 ng/liter in traditional units) when measured by either the Nichols Institute Diagnostics au- tomated chemiluminescence immunoassay (previously widely used but recently withdrawn) or the Bio-Rad Renin II RIA. Be- cause DRC assays are still in evolution, these conversion factors may change. For example, 1 ng/ml·h PRA converts to a DRC of approximately 12 mU/liter (7.6 ng/liter) when measured by the recently introduced and already widely used Diasorin automated chemiluminescence immunoassay. Here, we express aldosterone and PRA levels in conventional units (aldosterone in nanograms per deciliter; PRA in nanograms per milliliter per hour) with SI units for aldosterone and DRC (using the 8.2 conversion factor) given in parentheses. Lack of uniformity in diagnostic protocols and assay methods for ARR measurement has been associated with substantial variability in cutoff values used by different groups rang- ing from 20-100 (68-338) (11, 14, 15, 19, 29, 53, 54). Most groups, however, use cutoffs of 20-40 (68-135) when testing is performed in the morning on a seated ambulatory patient. Table 5 lists ARR cutoff values using some commonly expressed assay units for plasma aldosterone concentration (PAC), PRA, and direct mea- surement of plasma renin concentration.
| Drug | Class | Usual dose | Comments |
|---|---|---|---|
| Verapamil slow-release | Non-dihydropyridine calcium channel antagonist | 90-120 mg twice daily | Use singly or in combination with the other agents listed in this table. |
| Hydralazine | Vasodilator | 10-12.5 mg twice daily, increasing as required | Commence verapamil slow release first to prevent reflex tachycardia. Commencement at low doses reduces risk of side effects (including headaches, flushing, and palpitations). |
| Prazosin hydrochloride | @-Adrenergic blocker | 0.5-1 mg two to three times daily, increasing as required | Monitor for postural hypotension |
| Doxazosin mesylate | @-Adrenergic blocker | 1-2 mg once daily, increasing as required | Monitor for postural hypotension |
| Terazosin hydrochloride | @-Adrenergic blocker | 1-2 mg once daily, increasing as required | Monitor for postural hypotension |
Some investigators require elevated aldosterone levels in addi- tion to elevated ARR for a positive screening test for PA [usually aldosterone >15 ng/dl (416 pmol/liter)] (55). An alternative ap- proach is to avoid a formal cutoff level for plasma aldosterone but to recognize that the likelihood of a false-positive ARR becomes greater when renin levels are very low (11). Against a formal cutoff level for aldosterone are the findings of several studies. In one study, seated plasma aldosterone levels were less than 15 ng/dl (<416 pmol/liter) in 36% of 74 patients diagnosed with PA after screening positive by ARR defined as more than 30 (>100) and showing
failure of aldosterone to suppress during fludrocortisone suppres- sion testing (FST), and in four of 21 patients found by AVS to have unilateral, surgically correctable PA (56). Another study reported plasma aldosterone levels of 9-16 ng/dl (250-440 pmol/liter) in 16 of 37 patients diagnosed with PA by FST (16). Although it would clearly be desirable to provide firm recommendations for ARR and plasma aldosterone cutoffs, the variability of assays between lab- oratories and the divided literature to date make it more prudent to point out relative advantages and disadvantages, leaving clinicians the flexibility to judge for themselves.
TABLE 3. Measurement of the ARR: a suggested approach
ARR measurement
A. Preparation for ARR measurement: agenda
1. Attempt to correct hypokalemia, after measuring plasma potassium in blood collected slowly with a syringe and needle (preferably not a Vacutainer to minimize the risk of spuriously raising potassium); avoid fist clenching during collection; wait at least 5 sec after tourniquet release (if used to achieve insertion of needle) and ensure separation of plasma from cells within 30 min of collection.
2. Encourage patient to liberalize (rather than restrict) sodium intake.
3. Withdraw agents that markedly affect the ARR (48) for at least 4 wk:
a. Spironolactone, eplerenone, amiloride, and triamterene
b. Potassium-wasting diuretics
c. Products derived from licorice root (e.g. confectionary licorice, chewing tobacco)
4. If the results of ARR off the above agents are not diagnostic, and if hypertension can be controlled with relatively noninterfering medications (see Table 2), withdraw other medications that may affect the ARR (48) for at least 2 wk:
a. B-Adrenergic blockers, central @-2 agonists (e.g. clonidine and @-methyldopa), nonsteroidal antiinflammatory drugs
b. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, renin inhibitors, dihydropyridine calcium channel antagonists
5. If necessary to maintain hypertension control, commence other antihypertensive medications that have lesser effects on the ARR [e.g. verapamil slow-release, hydralazine (with verapamil slow-release, to avoid reflex tachycardia), prazosin, doxazosin, terazosin; see Table 2].
6. Establish OC and HRT status, because estrogen-containing medications may lower DRC and cause false-positive ARR when DRC (rather than PRA) is measured. Do not withdraw OC unless confident of alternative effective contraception.
B. Conditions for collection of blood
1. Collect blood mid-morning, after the patient has been up (sitting, standing, or walking) for at least 2 h and seated for 5-15 min.
2. Collect blood carefully, avoiding stasis and hemolysis (see A. 1 above).
3. Maintain sample at room temperature (and not on ice, because this will promote conversion of inactive to active renin) during delivery to laboratory and before centrifugation and rapid freezing of plasma component pending assay.
C. Factors to take into account when interpreting results (see Table 4)
1. Age: in patients aged >65 yr, renin can be lowered more than aldosterone by age alone, leading to a raised ARR
2. Time of day, recent diet, posture, and length of time in that posture
3. Medications
4. Method of blood collection, including any difficulty doing so
5. Level of potassium
6. Level of creatinine (renal failure can lead to false-positive ARR)
| Factor | Effect on aldosterone levels | Effect on renin levels | Effect on ARR |
|---|---|---|---|
| Medications | |||
| ß-Adrenergic blockers | 2 | 11 | ↑(FP) |
| Central @-2 agonists (e.g. clonidine and @-methyldopa) | 2 | 11 | ↑(FP) |
| NSAIDS | 2 | 1 (FP) | |
| K+-wasting diuretics | -> 1 | Į (FN) | |
| K+-sparing diuretics | 1 | 11 | Į (FN) |
| ACE inhibitors | 2 | 11 | Į (FN) |
| ARBs | 2 | 11 | Į (FN) |
| Ca2+ blockers (DHPs) | 1 | Į (FN) | |
| Renin inhibitors | 2 | 1 1ª | ↑(FP)。 |
| Į (FN)ª | |||
| Potassium status | |||
| Hypokalemia | 2 | Į (FN) | |
| Potassium loading | 1 | Î (FP) | |
| Dietary sodium | |||
| Sodium restricted | Į (FN) | ||
| Sodium loaded | 2 | Î (FP) | |
| Advancing age | 2 | 1 1 | Î (FP) |
| Other conditions | |||
| Renal impairment | -> | 1 | Î (FP) |
| PHA-2 | -> | 1 | Î (FP) |
| Pregnancy | 1 | Į (FN) | |
| Renovascular HT | 1 | Į (FN) | |
| Malignant HT | 1 | Į (FN) |
ACE, Angiotensin-converting enzyme; ARB, angiotensin II type 1 receptor blocker; DHP, dihydropyridine; FP, false positive; FN, false negative; HT, hypertension; NSAID, nonsteroidal antiinflammatory drug; PHA-2, pseudohypoaldosteronism type 2 (familial hypertension and hyperkalemia with normal glomerular filtration rate). a Renin inhibitors lower PRA but raise DRC. This would be expected to result in false-positive ARR levels for renin measured as PRA and false negatives for renin measured as DRC.
2.0 Case Confirmation
2.1 Instead of proceeding directly to subtype classification, we recommend that patients with a positive aldosterone-renin ratio (ARR) measurement undergo testing, by any of four confirmatory tests, to definitively confirm or exclude the di- agnosis (Fig. 1). (11+000)
2.1 Evidence
The current literature does not identify a gold standard confirmatory test for PA. Test performance has been evalu- ated only retrospectively, in relatively small series of patients selected with high prior (pretest) probability of PA, commonly in comparison with other tests rather than toward a conclusive diagnosis of PA.
Some of these limitations are illustrated in the following ex- ample. There is empirical evidence that case-control designs for establishing the accuracy of diagnostic tests overestimate their accuracy. Giacchetti et al. (57) used such a design including 61 PA patients (26 with confirmed APA) and 157 patients with essential hypertension. In this context, they found that a post- sodium infusion test (SIT) with a cutoff value for plasma aldo- sterone of at least 7 ng/dl showed a sensitivity of 88% and a specificity of 100% when evaluated by receiver-operating char- acteristic curve in the 76 cases with ARR more than 40 ng/dl per ng/ml.h. In the prospective PAPY study, analysis of sensitivity/ specificity in the 317 patients undergoing a SIT gave a best al- dosterone cutoff value of 6.8 ng/dl. The sensitivity and specific- ity, however, were moderate (respectively, 83 and 75%),
| PRA (ng/ml·h) | PRA (pmol/liter·min) | DRCª (mU/liter) | DRCª (ng/liter) | |
|---|---|---|---|---|
| PAC (ng/dl) | 20 | 1.6 | 2.4 | 3.8 |
| 30b | 2.5 | 3.7 | 5.7 | |
| 40 | 3.1 | 4.9 | 7.7 | |
| PAC (pmol/liter) | 750b | 60 | 91 | 144 |
| 1000 | 80 | 122 | 192 |
a Values shown are on the basis of a conversion factor of PRA (ng/ml-h) to DRC (mU/liter) of 8.2. DRC assays are still in evolution, and in a recently introduced and already commonly used automated DRC assay, the conversion factor is 12 (see text).
b The most commonly adopted cutoff values are shown in bold: 30 for PAC and PRA in conventional units (equivalent to 830 when PAC is in SI units) and 750 when PAC is expressed in SI units (equivalent to 27 in conventional units).
reflecting values overlapping between patients with and without disease; use of the aldosterone-cortisol ratio did not improve the accuracy of the test (17, 58).
Four testing procedures (oral sodium loading, saline infusion, fludrocortisone suppression, and captopril challenge) are in common use, and there is currently insufficient direct evidence to recommend one over the others. Although it is acknowledged that these tests may differ in terms of sensitivity, specificity, and reliability, the choice of confirmatory test is commonly deter- mined by considerations of cost, patient compliance, laboratory routine, and local expertise (Table 6). It should be noted that confirmatory tests requiring oral or iv sodium loading should be administered with caution in patients with uncontrolled hyper- tension or congestive heart failure. We recommend that the phar- macological agents with minimal or no effects on the renin-an- giotensin-aldosterone system shown in Table 2 be used to control blood pressure during confirmatory testing.
2.1 Values
Confirmatory testing places a high value on sparing individ- uals with false-positive ARR tests costly and intrusive lateral- ization procedures.
2.1 Remarks
For each of the four confirmatory tests, procedures, interpre- tations, and concerns are described in Table 6.
3.0 Subtype Classification
3.1 We recommend that all patients with PA undergo an ad- renal CT scan as the initial study in subtype testing and to exclude large masses that may represent adrenocortical car- cinoma (Fig. 1). (110000)
3.1 Evidence
The findings on adrenal CT-normal-appearing adrenals, unilateral macroadenoma (>1 cm), minimal unilateral adrenal limb thickening, unilateral microadenomas (≤1 cm), or bilateral macro- or microadenomas (or a combination of the two)-are used in conjunction with AVS and, if needed, ancillary tests to guide treatment decisions in patients with PA. APA may be vi- sualized as small hypodense nodules (usually <2 cm in diameter) on CT. IHA adrenal glands may be normal on CT or show nod- ular changes. Aldosterone-producing adrenal carcinomas are al- most always more than 4 cm in diameter, but occasionally smaller, and like most adrenocortical carcinomas have a suspi- cious imaging phenotype on CT (69).
Adrenal CT has several limitations. Small APAs may be in- terpreted incorrectly by the radiologist as IHA on the basis of CT findings of bilateral nodularity or normal-appearing adrenals. Moreover, apparent adrenal microadenomas may actually rep- resent areas of hyperplasia, and unilateral adrenalectomy would be inappropriate. In addition, nonfunctioning unilateral adrenal macroadenomas are not uncommon, especially in older patients (>40 yr) (70) and are indistinguishable from APAs on CT. Uni-
lateral UAH may be visible on CT, or the UAH adrenal may appear normal on CT.
In one study, CT contributed to lateralization in only 59 of 111 patients with surgically proven APA; CT detected fewer than 25% of the APAs that were smaller than 1 cm in diameter (62). In another study of 203 patients with PA who were evaluated with both CT and AVS, CT was accurate in only 53% of patients (71). On the basis of CT findings, 42 patients (22%) would have been incorrectly excluded as candidates for adrenalectomy, and 48 (25%) might have had unnecessary or inappropriate surgery (71). In a recent study, AVS was performed in 41 patients with PA, and concordance between CT and AVS was only 54% (72). Therefore, AVS is essential to direct appropriate therapy in pa- tients with PA who seek a potential surgical cure. CT is partic- ularly useful, however, for detecting larger lesions (e.g. >2.5 cm) that may warrant consideration for removal based on malignant potential and also for localizing the right adrenal vein as it enters into the inferior vena cava (IVC), thus aiding cannulation of the vein during AVS (73, 74).
3.1 Remarks
Magnetic resonance imaging has no advantage over CT in subtype evaluation of PA, being more expensive and having less spatial resolution than CT.
3.2 We recommend that, when surgical treatment is practi- cable and desired by the patient, the distinction between unilat- eral and bilateral adrenal disease be made by AVS by an expe- rienced radiologist (Fig. 1). (119000)
Evidence
Lateralization of the source of the excessive aldosterone se- cretion is critical to guide the management of PA. Distinguishing between unilateral and bilateral disease is important because unilateral adrenalectomy in patients with APA or UAH results in normalization of hypokalemia in all; hypertension is improved in all and cured in 30-60% (46, 75, 76). In bilateral IHA and GRA, unilateral or bilateral adrenalectomy seldom corrects the hyper- tension (77-81), and medical therapy is the treatment of choice (82). Unilateral disease may be treated medically if the patient declines or is not a candidate for surgery.
Imaging cannot reliably visualize microadenomas or distin- guish incidentalomas from APAs with confidence (71), making AVS the most accurate means of differentiating unilateral from bilateral forms of PA. AVS is expensive and invasive, and so it is highly desirable to avoid this test in patients who do not have PA (83). Because ARR testing can be associated with false positives, confirmatory testing should eliminate the potential for patients with false-positive ARR to undergo AVS.
The sensitivity and specificity of AVS (95 and 100%, respec- tively) for detecting unilateral aldosterone excess are superior to that of adrenal CT (78 and 75%, respectively) (62, 71, 72). Im- portantly, CT has the potential to be frankly misleading by dem- onstrating unilateral nodules in patients with bilateral disease and thereby to lead to inappropriate surgery.
AVS is the reference standard test to differentiate unilateral (APA or UAH) from bilateral (IHA) disease in patients with PA (62, 71). Although AVS can be a difficult procedure, especially
| Confirmatory test | Procedure | Interpretation | Concerns |
|---|---|---|---|
| Oral sodium loading test SIT FST Captopril challenge test | Patients should increase their sodium intake to >200 mmol/d (~6 g/d) for 3 d, verified by 24-h urine sodium content. Patients should receive adequate slow-release potassium chloride supplementation to maintain plasma potassium in the normal range. Urinary aldosterone is measured in the 24-h urine collection from the morning of d 3 to the morning of d 4. Patients stay in the recumbent position for at least 1 h before and during the infusion of 2 liters of 0.9% saline iv over 4 h, starting at 0800-0930 h. Blood samples for renin, aldosterone, cortisol, and plasma potassium are drawn at time zero and after 4 h, with blood pressure and heart rate monitored throughout the test. Patients receive 0.1 mg oral fludrocortisone every 6 h for 4 d, together with slow-release KCl supplements (every 6 h at doses sufficient to keep plasma K+, measured four times a day, close to 4.0 mmol/liter), slow-release NaCl supplements (30 mmol three times daily with meals) and sufficient dietary salt to maintain a urinary sodium excretion rate of at least 3 mmol/kg body weight. On d 4, plasma aldosterone and PRA are measured at 1000 h with the patient in the seated posture, and plasma cortisol is measured at 0700 and 1000 h. Patients receive 25-50 mg captopril orally after sitting or standing for at least 1 h. Blood samples are drawn for measurement of PRA, plasma aldosterone, and cortisol at time zero and at 1 or 2 h after challenge, with the patient remaining seated during this period. | PA is unlikely if urinary aldosterone is lower than 10 µg/24 h (27.7 nmol/ d) in the absence of renal disease where PA may coexist with lower measured urinary aldosterone levels. Elevated urinary aldosterone excretion [>12 µg/24 h (>33.3 nmol/d) at the Mayo Clinic, >14 µg/24 h (38.8 nmol/d) at the Cleveland Clinic] makes PA highly likely. Postinfusion plasma aldosterone levels <5 ng/dl make the diagnosis of PA unlikely, and levels >10 ng/ dl are a very probable sign of PA. Values between 5 and 10 ng/dl are indeterminate (57-60). | This test should not be performed in patients with severe uncontrolled hypertension, renal insufficiency, cardiac insufficiency, cardiac arrhythmia, or severe hypokalemia. The 24-h urine collection may be inconvenient. Laboratory-specific poor performance of the RIA for urinary aldosterone (aldosterone 18-oxo-glucuronide or acid- labile metabolite) may blunt diagnostic accuracy, a problem obviated by the currently available HPLC-tandem mass spectrometry methodology (52). Aldosterone 18-oxo-glucuronide is a renal metabolite, and its excretion may not rise in patients with renal disease. This test should not be performed in patients with severe uncontrolled hypertension, renal insufficiency, cardiac insufficiency, cardiac arrhythmia, or severe hypokalemia. |
| Upright plasma aldosterone >6 ng/dl on d 4 at 1000 h confirms PA, provided PRA is < 1 ng/ml-h and plasma cortisol concentration is lower than the value obtained at 0700 h (to exclude a confounding ACTH effect) (42, 43, 56, 61-63). Plasma aldosterone is normally suppressed by captopril (>30%). In patients with PA, it remains elevated and PRA remains suppressed. Differences may be seen between patients with APA and those with IHA, in that some decrease of aldosterone levels is occasionally seen in IHA (23, 64-66). | Although some centers (10, 16) conduct this test in the outpatient setting (provided that patients are able to attend frequently to monitor their potassium), in other centers, several days of hospitalization are customary. Most of the data available come from the Brisbane group (42, 43, 56, 61-63) who have established, on the basis of a very large series of patients, a cutoff of a plasma aldosterone concentration of 6 ng/dl at 1000 h in an ambulatory patient on d 4. Proponents of the FST argue that | ||
| 1) it is the most sensitive for confirming PA, 2) it is a less intrusive method of sodium loading than SIT and therefore less likely to provoke non-renin- dependent alterations of aldosterone levels, 3) it allows for the potentially confounding effects of potassium to be controlled and for ACTH (via cortisol) to be monitored and detected, and 4) it is safe when performed by experienced hands. There are reports of a substantial number of false-negative or equivocal results (67, 68). |
in terms of successfully cannulating the right adrenal vein (which is smaller than the left and usually empties directly into the IVC rather than the renal vein), the success rate usually improves quickly as the angiographer becomes more experienced. Accord- ing to a review of 47 reports, the success rate for cannulating the right adrenal vein in 384 patients was 74% (82). With experi- ence, the success rate increased to 90-96% (71, 73, 74, 84). The addition of rapid intraprocedural measurement of adrenal vein cortisol concentrations has facilitated improved accuracy of catheter placement in AVS (85). Some centers perform AVS in all patients who have the diagnosis of PA (62), and others advocate its selective use (e.g. AVS may not be needed in patients younger than age 40 with solitary unilateral apparent adenoma on CT scan) (71, 86).
At centers with experienced AVS radiologists, the complica- tion rate is 2.5% or lower (71, 73). The risk of adrenal hemor- rhage can be minimized by employing a radiologist skilled in the technique and by avoiding adrenal venography and limiting use of contrast to the smallest amounts necessary to assess the cath- eter tip position (74). Where there is a clinical suspicion of a procoagulant disorder, the risk of thromboembolism may be reduced by performing tests for such conditions before the pro- cedure and administering heparin after the procedure in patients at risk.
3.2 Values
Our recommendation to pursue AVS in the subtype evalua- tion of the patient with PA who is a candidate for surgery places a high value on avoiding the risk of an unnecessary unilateral adrenalectomy based on adrenal CT and a relatively low value on avoiding the potential complications of AVS.
3.2 Remarks
A radiologist experienced with and dedicated to AVS is needed to implement this recommendation.
There are three protocols for AVS: 1) unstimulated sequential or simultaneous bilateral AVS, 2) unstimulated sequential or simultaneous bilateral AVS followed by bolus cosyntropin-stim- ulated sequential or simultaneous bilateral AVS, and 3) contin- uous cosyntropin infusion with sequential bilateral AVS. Simul- taneous bilateral AVS is difficult to perform and is not used at most centers. Many groups advocate the use of continuous co- syntropin infusion during AVS 1) to minimize stress-induced fluctuations in aldosterone secretion during nonsimultaneous (sequential) AVS, 2) to maximize the gradient in cortisol from adrenal vein to IVC and thus confirm successful sampling of the adrenal vein, and 3) to maximize the secretion of aldosterone from an APA (71, 81, 84, 87) and thus avoid the risk of sampling during a relatively quiescent phase of aldosterone secretion.
The criteria used to determine lateralization of aldosterone hypersecretion depend on whether the sampling is done under cosyntropin administration. Dividing the right and left adrenal vein PACs by their respective cortisol concentrations corrects for dilutional effects of the inferior phrenic vein flowing into the left adrenal vein and, if suboptimally sampled, of IVC flow into the right adrenal vein. These are termed cortisol-corrected aldoste- rone ratios. With continuous cosyntropin administration, a cut-
off of the cortisol-corrected aldosterone ratio from high side to low side more than 4:1 is used to indicate unilateral aldosterone excess (71); a ratio less than 3:1 is suggestive of bilateral aldo- sterone hypersecretion (71). With these cutoffs, AVS for detect- ing unilateral aldosterone hypersecretion (APA or UAH) has a sensitivity of 95% and specificity of 100% (71). Patients with lateralization ratios between 3:1 and 4:1 may have either uni- lateral or bilateral disease, and the AVS results must be inter- preted in conjunction with the clinical setting, CT scan, and ancillary tests.
Some investigators consider a cortisol-corrected aldosterone lateralization ratio (high to low side) of more than 2:1 in the absence of cosyntropin as consistent with unilateral disease (83). Other groups rely primarily on comparing the adrenal vein al- dosterone-cortisol ratios to those in a simultaneously collected peripheral venous sample (62). When the aldosterone-cortisol ratio from an adrenal vein is significantly (usually at least 2.5 times) greater than that of the peripheral vein (cubital fossa or IVC), and the aldosterone-cortisol ratio in the contralateral ad- renal vein is no higher than peripheral (indicating contralateral suppression), the ratio is considered to show lateralization, an indication that unilateral adrenalectomy should cure or improve the hypertension.
Cosyntropin use
If cosyntropin infusion is not used, AVS should be performed in the morning hours after overnight recumbency. This approach avoids the confounding effects of changes in posture on aldo- sterone levels in patients with angiotensin II-responsive varieties of PA and takes advantage of the effect of high early morning endogenous ACTH levels on aldosterone production in all sub- types of PA (74).
If cosyntropin infusion is used, it may be continuous or bolus. For continuous cosyntropin, an infusion of 50 µg cosyntropin per hour is begun 30 min before adrenal vein catheterization and continued throughout the procedure (71, 81, 84). The bolus co- syntropin technique involves AVS before and after the iv admin- istration of 250 µg cosyntropin. However, some groups have suggested that when given as a bolus injection and when the adrenal veins are sampled simultaneously, cosyntropin admin- istration does not improve the diagnostic accuracy of AVS and that cosyntropin may in fact increase secretion from the non- adenomatous gland to a greater degree than from the APA (88).
Catheterization
The adrenal veins are catheterized through the percutaneous femoral vein approach, and the position of the catheter tip is verified by gentle injection of a small amount of nonionic con- trast medium and radiographic documentation (73). Blood is obtained from both adrenal veins and a peripheral vein, e.g. cubital fossa or iliac vein, and labeled peripheral and assayed for aldosterone and cortisol concentrations. To be sure there is no cross-contamination, the peripheral sample should be obtained from a cubital or iliac vein. The venous sample from the left side typically is obtained with the catheter tip at the junction of the inferior phrenic and left adrenal vein. The right adrenal vein may be especially difficult to catheterize because it is short and enters
the IVC at an acute angle (84). The cortisol concentrations from the adrenal veins and peripheral vein are used to confirm successful catheterization. The adrenal/peripheral vein corti- sol ratio is typically more than 10:1 with the continuous co- syntropin infusion protocol (71) and more than 3:1 without the use of cosyntropin (43).
Unsuccessful AVS
When both adrenal veins are not successfully catheterized, the clinician may 1) repeat AVS, 2) treat the patient with MR an- tagonist, or 3) consider surgery based on the findings of other studies (e.g. adrenal CT). Additional studies that may guide the clinician in this setting include posture stimulation test and io- docholesterol scintigraphy.
Posture stimulation test. In patients with unsuccessful AVS and with a CT scan showing a unilateral adrenal mass, some ex- perts use the posture stimulation test. This test, developed in the 1970s, was based on the finding that the PAC in patients with APA showed diurnal variation and was relatively unaf- fected by changes in angiotensin II levels, whereas IHA was characterized by enhanced sensitivity to a small change in angiotensin II that occurred with standing (89). In a review of 16 published reports, the accuracy of the posture stimulation test was 85% in 246 patients with surgically verified APA (82). The lack of accuracy is explained by the fact that some APAs are sensitive to angiotensin II and some patients with IHA have diurnal variation in aldosterone secretion (90). Thus, the posture stimulation test, particularly if it shows lack of responsiveness [consistent with angiotensin II-unrespon- sive APA or familial hyperaldosteronism type I (FH-I), with the latter readily confirmed or excluded by genetic testing] may serve an ancillary role, for example, in those patients for whom AVS was unsuccessful and CT shows a unilateral ad- renal mass (91, 92).
Iodocholesterol scintigraphy. [ 131I]19-Iodocholesterol scintig- raphy was first used in the early 1970s (93), and an improved agent, [60-131I]iodomethyl-19-norcholesterol (NP-59), was in- troduced in 1977 (94). The NP-59 scan, performed with dexa- methasone suppression, had the putative advantage of correlat- ing function with anatomical abnormalities. However, the sensitivity of this test depends heavily on the size of the adenoma (95, 96). Because tracer uptake was poor in adenomas smaller than 1.5 cm in diameter, this method often is not helpful in interpreting micronodular findings obtained with high-resolu- tion CT (97) and rarely plays a role in subtype evaluation. Cur- rently, it is no longer used in most centers.
18-Hydroxycorticosterone levels. 18-Hydroxycorticosterone is formed by 18-hydroxylation of corticosterone. Patients with APA generally have recumbent plasma 18-hydroxycorticoste- rone levels greater than 100 ng/dl at 0800 h, whereas patients with IHA have levels that are usually less than 100 ng/dl (98). However, this test lacks the accuracy needed to guide the clini- cian in the subtype evaluation of PA (82).
3.3 In patients with onset of confirmed PA earlier than at 20 yr of age and in those who have a family history of PA or of strokes at young age, we suggest genetic testing for GRA (Fig. 1). (210000)
3.3 Evidence
Testing for familial forms of PA: FH-I (GRA)
The FH-I syndrome is inherited in an autosomal dominant fashion and is responsible for fewer than 1% of cases of PA (99). GRA presentation is highly variable, with some patients present- ing with normal blood pressure and some characterized by al- dosterone excess, suppressed PRA, and hypertension of early onset that is usually severe and refractory to conventional anti- hypertensive therapies.
Some studies suggest a high pretest probability for GRA in children or young adults with severe or resistant hypertension and a positive family history of early-onset hypertension and/or premature hemorrhagic stroke (100, 101). In the study by Dluhy and colleagues (100), 50% of children under 18 yr of age with GRA had moderate or severe hypertension (blood pressure >99th percentile for age and sex) at diagnosis. Moreover, Litch- field et al. (101) reported in 376 patients from 27 genetically proven GRA pedigrees that 48% of all GRA pedigrees and 18% of all GRA patients had cerebrovascular complications, with the mean age at the time of the initial event being 32 ± 11.3 yr. Seventy percent of events were hemorrhagic strokes with an overall case fatality rate of 61% (101). The study design used in these reports does not allow estimation of the yield of new GRA patients that case detection could have in such populations.
Genetic testing by either Southern blot (102) or long PCR (103) techniques is sensitive and specific for GRA and obviates the need to measure the urinary levels of 18-oxocortisol and 18-hydroxycortisol or to perform dexamethasone suppression testing, both of which may be misleading (104). Genetic testing for GRA should be considered for PA patients with a family history of PA or of strokes at a young age (101, 105), or with an onset at a young age (e.g. < 20 yr).
Testing for familial forms of PA: FH-II
FH-II is an autosomal dominant disorder and possibly genet- ically heterogeneous (106). Unlike FH-I, the hyperaldosteronism in FH-II does not suppress with dexamethasone, and GRA mu- tation testing is negative (107). FH-II families may have APA, IHA, or both and are clinically indistinguishable from patients with apparent nonfamilial PA (108). Although FH-II is more common than FH-I, accounting for at least 7% of patients with PA in one series, its prevalence is unknown (108). The molecular basis for FH-II is unclear, although several linkage analyses have shown an association with chromosomal region 7p22 (106, 109).
Finally, APA may rarely but on occasion be seen in multiple endocrine neoplasia type 1.
4.0 Treatment
4.1 We recommend that unilateral laparoscopic adrenalec- tomy be offered to patients with documented unilateral PA (i.e. APA or UAH) (Fig. 1). (11000O) If a patient is unable or un-
willing to undergo surgery, we recommend medical treatment with an MR antagonist (Fig. 1). (119000)
4.1 Evidence
Unilateral laparoscopic adrenalectomy is used in patients with unilateral PA because blood pressure and serum potassium concentrations improve in nearly 100% of patients postopera- tively (76, 110-114). Hypertension is cured (defined as blood pressure <140/90 mm Hg without the aid of antihypertensive drugs) in about 50% (range, 35-60%) of patients with APA after unilateral adrenalectomy (75, 110), with a cure rate as high as 56-77% when the cure threshold was blood pressure less than 160/95 mm Hg (46, 115, 116). There is no high-quality evidence linking adrenalectomy with improved quality of life, morbidity, or mortality because studies of this nature have not, to our knowledge, been published.
Factors associated with resolution of hypertension in the postoperative period include having one or no first-degree rela- tive with hypertension and preoperative use of two or fewer antihypertensive drugs (76). Other factors have been reported to predict cure but have been evaluated by only univariate analysis or when the cutoff for blood pressure resolution was less than 160/95 mm Hg (46, 110, 113), duration of hypertension less than 5 yr (46, 47, 75, 76), higher PAC to PRA ratio preoperatively (75, 76), higher urinary aldosterone secretion (75, 76), or positive preoperative response to spironolactone (75, 111). The most common reasons for persistently increased blood pressure after adrenalectomy are coexistent hypertension of unknown cause (46, 76) and older age and/or longer duration of hypertension.
As compared with open adrenalectomy, laparoscopic adre- nalectomy is associated with shorter hospital stays and fewer complications (112, 117, 118). Because AVS is able to identify only which gland (and not which part of the gland) is overpro- ducing aldosterone, partial adrenalectomy (removal of an ade- noma leaving the remaining adrenal intact) may result in persis- tent hypertension; continued elevation of PAC is found in up to 10% of patients with unilateral APA, and 27% of extirpated adrenal glands are found to contain multiple nodules (119).
Medical management is recommended for patients who do not undergo surgery. In a retrospective study of 24 patients with APA who were treated for 5 yr with spironolactone or amiloride, systolic and diastolic blood pressure decreased from an average of 175/106 to 129/79 mm Hg (120) with 83% of these patients requiring additional antihypertensive medication to achieve this result. Furthermore, several of the patients experienced side ef- fects from the spironolactone therapy including breast tender- ness (54%), breast engorgement (33%), muscle cramps (29%), and decreased libido (13%). In the long term, adrenalectomy is more cost effective than lifelong medical therapy for patients with unilateral PA (121).
Therefore, because unilateral laparoscopic adrenalectomy can either eliminate the need for medication or reduce medica- tion-related side effects, it is the preferred procedure for the treat- ment of unilateral disease in patients with PA.
4.1 Values
Our recommendation to subject patients with unilateral ad- renal disease to laparoscopic adrenalectomy in preference to other methods of treatment places a high value on reduction of blood pressure and/or the number of medications necessary to control blood pressure, on normalization of endogenous aldo- sterone secretion, and on the resolution of hypokalemia. This benefit is far greater than the risks of surgery and postoperative management, which are extremely low.
4.1 Remarks
This recommendation requires the availability of a surgeon experienced in laparoscopic adrenalectomy.
Preoperative management
In the patient scheduled for surgery, both hypertension and hypokalemia should be well controlled preoperatively. Obtain- ing such control may require a delay in surgery and the addition of an MR antagonist.
Postoperative management
Plasma aldosterone and renin activity levels should be mea- sured shortly after surgery as an early indication of biochemical response (114), and on postoperative d 1, potassium supplemen- tation should be withdrawn, spironolactone discontinued, and antihypertensive therapy reduced, if appropriate (122).
Postoperative iv fluids should be normal saline without po- tassium chloride unless serum potassium levels remain very low (i.e. < 3.0 mmol/liter), and during the first few weeks after sur- gery, a generous sodium diet should be recommended to avoid the hyperkalemia that can develop from hypoaldosteronism due to chronic contralateral adrenal gland suppression (122). In rare instances, temporary fludrocortisone therapy may be required.
Blood pressure typically normalizes or shows maximal im- provement in 1-6 months after unilateral adrenalectomy for unilateral APA but can continue to fall for up to 1 yr in some patients. Some investigators have employed postoperative FST (performed at least 3 months after surgery to permit recovery of the contralateral gland) to assess whether the PA has been cured from a biochemical perspective (123).
4.2 In patients with PA due to bilateral adrenal disease, we recommend medical treatment with an MR antagonist (110000); we suggest spironolactone as the primary agent with eplerenone as an alternative (Fig. 1). (210000)
4.2 Evidence
Bilateral adrenal disease includes idiopathic adrenal hyper- plasia, bilateral APA, and GRA. In 99 surgically treated patients with IHA reported in the literature, the hypertension cure rate was only 19% after unilateral or bilateral adrenalectomy (77- 81). No randomized placebo-controlled trials have evaluated the relative efficacy of drugs in the treatment of PA. However, the pathophysiology of PA due to bilateral adrenal hyperplasia and longstanding clinical experience suggest several pharmacologi- cal targets.
MR antagonists
MR antagonists appear to be effective at controlling blood pressure and to provide blood pressure-independent target organ protection.
Spironolactone
For more than four decades, the MR antagonist spironolac- tone has been the agent of choice in the medical treatment of PA. Several observational studies in patients with IHA (combined n = 122) have reported a mean reduction in systolic blood pres- sure of 25% and diastolic blood pressure of 22% in response to spironolactone 50-400 mg/d for 1-96 months (124-130). In a study of 28 hypertensive subjects with an ARR more than 750 pmol/liter (27 ng/dl) per ng/ml·h who failed to suppress their PAC after salt loading and without evidence of adenoma on adrenal CT scan, spironolactone therapy (25-50 mg/d) reduced the need for antihypertensive drugs by -0.5 (from a mean of 2.3 to 1.8 drugs) drugs, as well as reducing systolic blood pressure by -15 mm Hg (from a mean of 161 to 146 mm Hg) and diastolic blood pressure by -8 mm Hg (from a mean of 91 to 83 mm Hg); 48% of subjects achieved a blood pressure less than 140/90 mm Hg, and about half were able to be managed with spironolactone monotherapy (131). The dose of spironolactone employed in that study was much lower than previously considered necessary for the treatment of PA.
The incidence of gynecomastia with spironolactone therapy is dose related, with one study reporting an incidence after 6 months of 6.9% at a dose of less than 50 mg/d and 52% at a dose of more than 150 mg/d (132). The exact incidence of menstrual disturbances in premenopausal women with spironolactone therapy is unknown. Where available, canrenone (an active me- tabolite of spironolactone) or potassium canrenoate, its open E-ring water-soluble congener, might be considered, in that they possibly have fewer sex steroid-related side effects. In addition, a small dose of a thiazide diuretic, triamterine, or amiloride can be added to attempt to avoid a higher dose of spironolactone, which may cause side effects.
Eplerenone
Eplerenone is a newer, selective MR antagonist without an- tiandrogen and progesterone agonist effects (133), thus reducing the rate of adverse endocrine side effects. It has been approved for the treatment of primary (essential) hypertension (134, 135) in the United States and Japan and for heart failure after myo- cardial infarction (136) in the United States and a number of other countries. Eplerenone has 60% of the MR antagonist po- tency of spironolactone; its better tolerability profile needs to be balanced against its higher cost and the lack of current clinical trial evidence for its use in PA. Reflecting its shorter half-life, eplerenone should be given twice daily for optimal effect.
Other agents
Up-regulation of distal tubular sodium epithelial channel ac- tivity is a major mechanism whereby aldosterone exerts its ac- tions on sodium and potassium handling. Of the available epi- thelial sodium channel antagonists (amiloride and triamterene), amiloride has been the most studied as a mode of treatment for
PA. Although less efficacious than spironolactone, amiloride may be useful (28, 137). Being a potassium-sparing diuretic, amiloride can ameliorate both hypertension and hypokalemia in patients with PA and is generally well tolerated, lacking the sex steroid-related side effects of spironolactone, but without the beneficial effects on endothelial function (138, 139).
Calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers have been evalu- ated in very few patients with PA, and in general, they are anti- hypertensive without a major effect on aldosterone excess. Sup- portive studies are small and methodologically weak and have not measured patient-important outcomes. Aldosterone syn- thase inhibitors may play a role in the future.
4.2 Values
This recommendation places a relatively higher value on re- duction of blood pressure normalization of serum potassium concentrations and abrogation of the vascular, cardiac, and renal effects of aldosterone with the minimum number of pharmaco- logical agents and a relatively lower value on side effects such as gynecomastia and erectile dysfunction in men and menstrual irregularities in women. Eplerenone, given its selectivity and de- spite its cost, is an alternative if the side effects of spironolactone prove difficult to tolerate.
4.2 Remarks
The starting dose for spironolactone should be 12.5-25 mg daily in a single dose. The lowest effective dose should be found by very gradually titrating upward if necessary to a maximum dose of 100 mg/d. The starting dose for eplerenone is 25 mg once or twice daily. In patients with stage III chronic kidney disease (i.e. glomerular filtration rate <60 ml/min.1.73m2), spironolac- tone and eplerenone may be used with caution because of the risk of hyperkalemia, but MR antagonists should be avoided in those with stage IV disease.
4.3 In patients with GRA, we recommend the use of the lowest dose of glucocorticoid that can normalize blood pressure and potassium levels rather than first-line treatment with an MR antagonist (Fig. 1). (110000)
4.3 Evidence
GRA should be treated medically with a glucocorticoid to partially suppress pituitary ACTH secretion. We recommend use of a synthetic glucocorticoid that is longer acting than hydro- cortisone, such as dexamethasone or prednisone, to suppress ACTH secretion. Ideally, the glucocorticoid should be taken at bedtime to suppress the early morning ACTH surge. PRA and aldosterone concentrations may be helpful in assessing the ef- fectiveness of treatment and the prevention of overtreatment.
Overtreatment with exogenous steroids must be avoided; iat- rogenic Cushing’s syndrome and impaired linear growth in chil- dren have resulted from such overdosing (100). In general, the lowest possible dose of glucocorticoid that normalizes blood pressure and/or serum potassium concentration should be used (74). Treatment with a glucocorticoid may not always normalize blood pressure, and addition of an MR antagonist should be considered in these cases.
The use of eplerenone may be preferred in the case of affected children, in whom there may be concerns with respect to growth retardation and antiandrogenic effects of glucocorticoids and spironolactone, respectively.
4.3 Values
The treatment of GRA places a high value on preventing the potential consequences of hyperaldosteronism and a lower value on the possible side effects of chronic glucocorticoid administration.
4.3 Remarks
The starting dose of dexamethasone in adults is 0.125-0.25 mg daily. The starting dose of prednisone is 2.5-5 mg daily. For each, treatment is usually administered at bedtime.
Acknowledgments
In addition to the members of the Task Force, there have been a number of people whose contribution to these guidelines has been invaluable. First, we thank Dr. Robert Vigersky, the members of the Clinical Guide- lines Subcommittee, the Clinical Affairs Core Committee, and the Coun- cil of The Endocrine Society for their careful reading of and very useful suggestions for improving the guidelines. Second, we thank the members of The Endocrine Society at large for their input when the draft guidelines were posted on the Society’s website; all the responses received were considered by the authors, and many incorporated. Third, we thank the members of our sister societies around the world for their enthusiastic involvement in reading the draft guidelines, and in offering their support for this publication. Fourth, we thank Lisa Marlow of The Endocrine Society, who has provided first-class administrative and logistic back-up, without which such a geographically disperse task force would have faced considerable difficulty in operating. Last, but very much not least, we are indebted to Dr. Patricia A. Stephens, medical writer, for her unfailing patience, her meticulous checking of both text and references, and most importantly her ability to meld half a dozen disparate writing styles into a seamless whole.
Address all correspondence and requests for reprints to: The Endo- crine Society, 8401 Connecticut Avenue, Suite 900, Chevy Chase, Mary- land 20815. E-mail: govt-prof@endo.society.org. Telephone: 301-941- 0200. Address all reprint requests for orders 101 and more to: Heather Edwards, Reprint Sales Specialist, Cadmus Professional Communi- cations, Telephone: 410-691-6214, Fax: 410-684-2789 or by E-mail: endoreprints@cadmus.com. Address all reprint requests for orders 100 or less to Society Services, Telephone: 301-941-0210 or by E-mail: societyservices@endo-society.org.
Cosponsoring organizations include the European Society of Endo- crinology, European Society of Hypertension, International Society of Endocrinology, International Society of Hypertension, and The Japanese Society of Hypertension.
Disclaimer
Clinical Practice Guidelines are developed to be of assistance to endo- crinologists by providing guidance and recommendations for particular areas of practice. The Guidelines should not be considered inclusive of all proper approaches or methods, or exclusive of others. The Guidelines cannot guarantee any specific outcome, nor do they establish a standard of care. The Guidelines are not intended to dictate the treatment of a particular patient. Treatment decisions must be made based on the in-
dependent judgment of health care providers and each patient’s individ- ual circumstances.
The Endocrine Society makes no warranty, express or implied, re- garding the Guidelines and specifically excludes any warranties of mer- chantability and fitness for a particular use or purpose. The Society shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein.
Financial Disclosure of Task Force
John W. Funder, M.D., Ph.D. (chair) - Financial or Business/Organiza- tional Interests: Schering-Plough, Daiichi-Sankyo, Pfizer, Cancer Insti- tute of New South Wales, Speedel, Garnett Passe and Rodney Williams Memorial Foundation, Merck, Eli Lilly, P3 Panel (Commonwealth of Australia); Significant Financial Interest or Leadership Position: Scher- ing-Plough, Pfizer, Daiichi-Sankyo, and Cancer Institute of New South Wales. Robert M. Carey, M.D. - Financial or Business/Organizational Interests: Novartis, Pfizer, and Daiichi-Sankyo; Significant Financial In- terest or Leadership Position: none declared. Carlos Fardella, M.D. - Financial or Business/Organizational Interests: National Fund for Sci- entific and Technological Development (Fondo Nacional de Desarrollo Científico y Tecnológico [FONDECYT]); Significant Financial Interest or Leadership Position: none declared. Celso E. Gomez-Sanchez, M.D. - Financial or Business/Organizational Interests: American Heart Asso- ciation; Significant Financial Interest or Leadership Position: Associate Editor for the journal Hypertension. Franco Mantero, M.D., Ph.D. - Financial or Business/Organizational Interests: none declared; Signifi- cant Financial Interest or Leadership Position: Executive Committee of the International Society of Endocrinology. Michael Stowasser, MBBS, FRACP, Ph.D. - Financial or Business/Organizational Interests: none declared; Significant Financial Interest or Leadership Position: none de- clared. William F. Young Jr., M.Sc., M.D. - Financial or Business/Or- ganizational Interests: none declared; Significant Financial Interest or Leadership Position: Mayo Clinic, Clinical Endocrinology. * Victor M. Montori, M.D. - Financial or Business/Organizational Interests: KER Unit (Mayo Clinic); Significant Financial Interest or Leadership Position: none declared.
References
1. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer TT, Varonen H, Vist GE, Williams Jr JW, Zaza S 2004 Grading quality of evidence and strength of recommenda- tions. BMJ 328:1490
2. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of- the-art clinical practice guidelines in endocrinology using the grading of rec- ommendations, assessment, development, and evaluation system. J Clin En- docrinol Metab 93:666-673
3. Andersen GS, Toftdahl DB, Lund JO, Strandgaard S, Nielsen PE 1988 The incidence rate of phaeochromocytoma and Conn’s syndrome in Denmark, 1977-1981. J Hum Hypertens 2:187-189
4. Berglund G, Andersson O, Wilhelmsen L 1976 Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 2:554-556
5. Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT 1968 Incidence of primary aldosteronism uncomplicated “essential” hyper- tension. A prospective study with elevated aldosterone secretion and sup- pressed plasma renin activity used as diagnostic criteria. JAMA 205:497-502
6. Kaplan NM 1967 Hypokalemia in the hypertensive patient, with obser- vations on the incidence of primary aldosteronism. Ann Intern Med 66: 1079-1090
7. Streeten DH, Tomycz N, Anderson GH 1979 Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med 67:403-413
8. Tucker RM, Labarthe DR 1977 Frequency of surgical treatment for hyper-
tension in adults at the Mayo Clinic from 1973 through 1975. Mayo Clin Proc 52:549-545
9. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW 1987 Secondary hypertension in a blood pressure clinic. Arch Intern Med 147:1289-1293
10. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J 2000 Primary hyperal- dosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85:1863-1867
11. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC 1994 High incidence of primary aldosteronism in 199 patients referred with hyperten- sion. Clin Exp Pharmacol Physiol 21:315-318
12. Grim CE, Weinberger MH, Higgins JT, Kramer NJ 1977 Diagnosis of secondary forms of hypertension. A comprehensive protocol. JAMA 237: 1331-1335
13. Hamlet SM, Tunny TJ, Woodland E, Gordon RD 1985 Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol 12:249-252
14. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM 2000 High preva- lence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14:311-315
15. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young Jr WF 2000 Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85:2854-2859
16. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE 2003 Primary aldosteronism and hypertensive dis- ease. Hypertension 42:161-165
17. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F 2006 A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48:2293-2300
18. Schwartz GL, Turner ST 2005 Screening for primary aldosteronism in es- sential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51:386-394
19. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young Jr WF 2004 Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89:1045-1050
20. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F 2006 Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 48:232-238
21. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldo- steronism. J Am Coll Cardiol 45:1243-1248
22. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH 2005 Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 90:5070-5076
23. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F 2002 High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15:896-902
24. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky Jr J 2003 Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 17:349-352
25. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR 2006 Prevalence of primary hyperaldosteronism in mild to mod- erate hypertension without hypokalaemia. J Hum Hypertens 20:129-136
26. Benchetrit S, Bernheim J, Podjarny E 2002 Normokalemic hyperaldosteron- ism in patients with resistant hypertension. Isr Med Assoc J 4:17-20
27. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P 2002 Hyperaldosteronism among black and white subjects with resistant hyper- tension. Hypertension 40:892-896
28. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP 2004 Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hy- pertens 22:2217-2226
29. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC 2001 Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37:699-705
30. Goodfriend TL, Calhoun DA 2004 Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43:518-524
31. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM 2004 Aldosterone
excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125:112-117
32. Aso Y, Homma Y 1992 A survey on incidental adrenal tumors in Japan. J Urol 147:1478-1481
33. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M 2003 Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 149:273-285
34. Bulow B, Ahren B 2002 Adrenal incidentaloma: experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med 252: 239-246
35. Caplan RH, Strutt PJ, Wickus GG 1994 Subclinical hormone secretion by incidentally discovered adrenal masses. Arch Surg 129:291-296
36. Kim HY, Kim SG, Lee KW, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS 2005 Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 20:303-309
37. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A 2000 A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85:637-644
38. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC 1996 Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039-1045
39. Montori VM, Young Jr WF 2002 Use of plasma aldosterone concentration- to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 31: 619-632, xi
40. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T 1981 A screening test to identify aldosterone-pro- ducing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 141:1589-1593
41. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S 1991 Diagnosis under random conditions of all disorders of the renin-angiotensin- aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 73:952-957
42. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM 2003 High rate of detection of primary aldosteronism, in- cluding surgically treatable forms, after ‘non-selective’ screening of hyper- tensive patients. J Hypertens 21:2149-2157
43. Gordon RD 1995 Primary aldosteronism. J Endocrinol Invest 18:495-511
44. Stowasser M, Gordon RD 2004 The aldosterone-renin ratio for screening for primary aldosteronism. Endocrinologist 14:267-276
45. Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K 2003 Vari- ability in the renin/aldosterone profile under random and standardized sam- pling conditions in primary aldosteronism. J Clin Endocrinol Metab 88:2489-2494
46. Celen O, O’Brien MJ, Melby JC, Beazley RM 1996 Factors influencing out- come of surgery for primary aldosteronism. Arch Surg 131:646-650
47. Streeten DH, Anderson Jr GH, Wagner S 1990 Effect of age on response of secondary hypertension to specific treatment. Am J Hypertens 3:360-365
48. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F 2002 Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40:897-902
49. Montori VM, Schwartz GL, Chapman AB, Boerwinkle E, Turner ST 2001 Validity of the aldosterone-renin ratio used to screen for primary aldoste- ronism. Mayo Clin Proc 76:877-882
50. Sealey JE, Laragh JH 1975 Radioimmunoassay of plasma renin activity. Se- min Nucl Med 5:189-202
51. Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M 2006 Automated chemiluminescence-immunoassay for aldosterone during dy- namic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 52:1749-1755
52. Guo T, Taylor RL, Singh RJ, Soldin SJ 2006 Simultaneous determination of 12 steroids by isotope dilution liquid chromatography-photospray ionization tandem mass spectrometry. Clin Chim Acta 372:76-82
53. Tiu SC, Choi CH, Shek CC, Ng YW, Chan FK, Ng CM, Kong AP 2005 The use of aldosterone-renin ratio as a diagnostic test for primary hyperaldoste- ronism and its test characteristics under different conditions of blood sam- pling. J Clin Endocrinol Metab 90:72-78
54. Young Jr WF 1997 Primary aldosteronism: update on diagnosis and treat- ment. Endocrinologist 7:213-221
55. Young WF 2007 Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf) 66:607-618
56. Stowasser M, Gordon RD 2004 Primary aldosteronism: careful investigation is essential and rewarding. Mol Cell Endocrinol 217:33-39
57. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F 2006 Analysis
of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24:737-745
58. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Semplicini A, Agabiti-Rosei E, Pessina AC, Mantero F 2007 Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. J Hypertens 25:1433-1442
59. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez CE 1984 Further evaluation of saline infusion for the diagnosis of primary al- dosteronism. Hypertension 6:717-723
60. Kem DC, Weinberger MH, Mayes DM, Nugent CA 1971 Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 128:380-386
61. Gordon RD 1994 Mineralocorticoid hypertension. Lancet 344:240-243
62. Gordon RD 2001 Diagnostic investigations in primary aldosteronism. In: Zanchetti A, ed. Clinical medicine series on hypertension. Maidenhead, UK: McGraw-Hill International; 101-111
63. Gordon RD, Stowasser M, Klemm SA, Tunny TJ 1994 Primary aldosteron- ism and other forms of mineralocorticoid hypertension. In: Swales J, ed Text- book of hypertension. London: Blackwell Scientific; 865-892
64. Agharazii M, Douville P, Grose JH, Lebel M 2001 Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37: 1440-1443
65. Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C 1981 Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci (Lond) 61(Suppl 7):289s-293s
66. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F 2007 Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 50:424-431
67. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA 1992 Re-eval- uation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 36:499-503
68. Mulatero P, Bertello C, Garrone C, Rossato D, Mengozzi G, Verhovez A, Fallo F, Veglio F 2007 Captopril test can give misleading results in patients with suspect primary aldosteronism. Hypertension 50:e26-e27
69. Young Jr WF 2007 Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356:601-610
70. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B 1995 Incidentally discovered adrenal masses. Endocr Rev 16:460-484
71. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA 2004 Role for adrenal venous sampling in primary aldosteronism. Surgery 136:1227-1235
72. Nwariaku FE, Miller BS, Auchus R, Holt S, Watumull L, Dolmatch B, Nesbitt S, Vongpatanasin W, Victor R, Wians F, Livingston E, Snyder 3rd WH 2006 Primary hyperaldosteronism: effect of adrenal vein sampling on surgical out- come. Arch Surg 141:497-502
73. Daunt N 2005 Adrenal vein sampling: how to make it quick, easy, and suc- cessful. Radiographics 25(Suppl 1):S143-S158
74. Stowasser M, Gordon RD 2001 Familial hyperaldosteronism. J Steroid Bio- chem Mol Biol 78:215-229
75. Meyer A, Brabant G, Behrend M 2005 Long-term follow-up after adrenal- ectomy for primary aldosteronism. World J Surg 29:155-159
76. Sawka AM, Young WF, Thompson GB, Grant CS, Farley DR, Leibson C, van Heerden JA 2001 Primary aldosteronism: factors associated with normal- ization of blood pressure after surgery. Ann Intern Med 135:258-261
77. Baer L, Sommers SC, Krakoff LR, Newton MA, Laragh JH 1970 Pseudo- primary aldosteronism. An entity distinct from true primary aldosteronism. Circ Res 27:203-220
78. Gunnells Jr JC, Bath NM, Sode J, Robinson RR 1967 Primary aldosteronism. Arch Intern Med 120:568-574
79. Priestley JT, Ferris DO, ReMine WH, Woolner LB 1968 Primary aldoste- ronism: surgical management and pathologic findings. Mayo Clin Proc 43: 761-775
80. Rhamy RK, McCoy RM, Scott Jr HW, Fishman LM, Michelakis AM, Liddle GW 1968 Primary aldosteronism: experience with current diagnostic criteria and surgical treatment in fourteen patients. Ann Surg 167:718-727
81. Weinberger MH, Grim CE, Hollifield JW, Kem DC, Ganguly A, Kramer NJ, Yune HY, Wellman H, Donohue JP 1979 Primary aldosteronism: diagnosis, localization, and treatment. Ann Intern Med 90:386-395
82. Young Jr WF, Klee GG 1988 Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am 17:367-395
83. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin
GP, Pessina AC 2001 Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 86:1083-1090
84. Doppman JL, Gill Jr JR 1996 Hyperaldosteronism: sampling the adrenal veins. Radiology 198:309-312
85. Mengozzi G, Rossato D, Bertello C, Garrone C, Milan A, Pagni R, Veglio F, Mulatero P 2007 Rapid cortisol assay during adrenal vein sampling in pa- tients with primary aldosteronism. Clin Chem 53:1968-1971
86. Tan YY, Ogilvie JB, Triponez F, Caron NR, Kebebew EK, Clark OH, Duh QY 2006 Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. World J Surg 30:879-885
87. Carr CE, Cope C, Cohen DL, Fraker DL, Trerotola SO 2004 Comparison of sequential versus simultaneous methods of adrenal venous sampling. J Vasc Interv Radiol 15:1245-1250
88. Rossi GP, Ganzaroli C, Miotto D, De Toni R, Palumbo G, Feltrin GP, Mantero F, Pessina AC 2006 Dynamic testing with high-dose adrenocorti- cotrophic hormone does not improve lateralization of aldosterone overse- cretion in primary aldosteronism patients. J Hypertens 24:371-379
89. Ganguly A, Dowdy AJ, Luetscher JA, Melada GA 1973 Anomalous postural response of plasma aldosterone concentration in patients with aldosterone- producing adrenal adenoma. J Clin Endocrinol Metab 36:401-404
90. Gordon RD, Gomez-Sanchez CE, Hamlet SM, Tunny TJ, Klemm SA 1987 Angiotensin-responsive aldosterone-producing adenoma masquerades as id- iopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin essen- tial hypertension. J Hypertens Suppl 5:S103-S106
91. Espiner EA, Ross DG, Yandle TG, Richards AM, Hunt PJ 2003 Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J Clin Endocrinol Metab 88:3637-3644
92. Phillips JL, Walther MM, Pezzullo JC, Rayford W, Choyke PL, Berman AA, Linehan WM, Doppman JL, Gill Jr JR 2000 Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone- producing adrenal adenoma. J Clin Endocrinol Metab 85:4526-4533
93. Conn JW, Morita R, Cohen EL, Beierwaltes WH, McDonald WJ, Herwig KR 1972 Primary aldosteronism. Photoscanning of tumors after administration of 1311-19-iodocholesterol. Arch Intern Med 129:417-425
94. Sarkar SD, Cohen EL, Beierwaltes WH, Ice RD, Cooper R, Gold EN 1977 A new and superior adrenal imaging agent, 131I-6ß-iodomethyl-19-nor- cholesterol (NP-59): evaluation in humans. J Clin Endocrinol Metab 45: 353-362
95. Hogan MJ, McRae J, Schambelan M, Biglieri EG 1976 Location of aldoste- rone-producing adenomas with 131I-19-iodocholesterol. N Engl J Med 294: 410-414
96. Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H 1990 Iodom- ethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone- suppression scintigraphy: relationship to adenoma size and functional activ- ity. J Clin Endocrinol Metab 71:825-830
97. Mansoor GA, Malchoff CD, Arici MH, Karimeddini MK, Whalen GF 2002 Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 15:459-464
98. Biglieri EG, Schambelan M 1979 The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. J Clin En- docrinol Metab 49:87-91
99. McMahon GT, Dluhy RG 2004 Glucocorticoid-remediable aldosteronism. Cardiol Rev 12:44-48
100. Dluhy RG, Anderson B, Harlin B, Ingelfinger J, Lifton R 2001 Glucocorti- coid-remediable aldosteronism is associated with severe hypertension in early childhood. J Pediatr 138:715-720
101. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG 1998 Intra- cranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable al- dosteronism. Hypertension 31:445-450
102. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM 1992 A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glu- cocorticoid-remediable aldosteronism and human hypertension. Nature 355:262-265
103. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD 1995 A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 207:565-571
104. Fardella CE, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J, Montero J 2001 Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab 86:4805-4807
105. Gates LJ, Benjamin N, Haites NE, MacConnachie AA, McLay JS 2001 Is random screening of value in detecting glucocorticoid-remediable aldoste- ronism within a hypertensive population? J Hum Hypertens 15:173-176
106. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M 2005 Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 23:1477-1484
107. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL 1991 Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 18:283-286
108. Stowasser M, Gordon RD 2003 Primary aldosteronism: from genesis to ge- netics. Trends Endocrinol Metab 14:310-317
109. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA 2000 A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 37:831-835
110. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan Jr ED, Sos TA, Atlas SA, Muller FB, Acevedo R, Ulick S, Laragh JH 1994 Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 121:877-885
111. Harris DA, Au-Yong I, Basnyat PS, Sadler GP, Wheeler MH 2003 Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur J Surg Oncol 29:467-474
112. Rossi H, Kim A, Prinz RA 2002 Primary hyperaldosteronism in the era of laparoscopic adrenalectomy. Am Surg 68:253-256; discussion 256-257
113. Stowasser M, Klemm SA, Tunny TJ, Storie WJ, Rutherford JC, Gordon RD 1994 Response to unilateral adrenalectomy for aldosterone-producing ade- noma: effect of potassium levels and angiotensin responsiveness. Clin Exp Pharmacol Physiol 21:319-322
114. Young Jr WF 2003 Primary aldosteronism: changing concepts in diagnosis and treatment. Endocrinology 144:2208-2213
115. Lo CY, Tam PC, Kung AW, Lam KS, Wong J 1996 Primary aldosteronism. Results of surgical treatment. Ann Surg 224:125-130
116. Proye CA, Mulliez EA, Carnaille BM, Lecomte-Houcke M, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, Ernst O, Huglo D, Carre A 1998 Es- sential hypertension: first reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery 124:1128-1133
117. Jacobsen NE, Campbell JB, Hobart MG 2003 Laparoscopic versus open adrenalectomy for surgical adrenal disease. Can J Urol 10:1995-1999
118. Rutherford JC, Stowasser M, Tunny TJ, Klemm SA, Gordon RD 1996 Lapa- roscopic adrenalectomy. World J Surg 20:758-760; discussion 761
119. Ishidoya S, Ito A, Sakai K, Satoh M, Chiba Y, Sato F, Arai Y 2005 Laparo- scopic partial versus total adrenalectomy for aldosterone producing ade- noma. J Urol 174:40-43
120. Ghose RP, Hall PM, Bravo EL 1999 Medical management of aldosterone- producing adenomas. Ann Intern Med 131:105-108
121. Sywak M, Pasieka JL 2002 Long-term follow-up and cost benefit of ad- renalectomy in patients with primary hyperaldosteronism. Br J Surg 89: 1587-1593
122. Mattsson C, Young Jr WF 2006 Primary aldosteronism: diagnostic and treat- ment strategies. Nat Clin Pract Nephrol 2:198-208
123. Rutherford JC, Taylor WL, Stowasser M, Gordon RD 1998 Success of sur- gery for primary aldosteronism judged by residual autonomous aldosterone production. World J Surg 22:1243-1245
124. Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI 1972 Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Br Med J 2:729-734
125. Crane MG, Harris JJ 1970 Effect of spironolactone in hypertensive patients. Am J Med Sci 260:311-330
126. Ganguly A, Luetscher JA 1976 Spironolactone therapy in primary aldoste- ronism: diagnostic and therapeutic implications. In: Sambhi MP, ed. Systemic effects of antihypertensive agents. New York: Stratton; 383-392
127. Helber A, Wambach G, Hummerich W, Bonner G, Meurer KA, Kaufmann W 1980 Evidence for a subgroup of essential hypertensives with non-sup- pressible excretion of aldosterone during sodium loading. Klin Wochenschr 58:439-447
128. Kater CE, Biglieri EG, Schambelan M, Arteaga E 1983 Studies of impaired aldosterone response to spironolactone-induced renin and potassium eleva- tions in adenomatous but not hyperplastic primary aldosteronism. Hyper- tension 5:V115-V121
129. Kremer D, Beevers DG, Brown JJ, Davies DL, Ferriss JB, Fraser R, Lever AF, Robertson JI 1973 Spironolactone and amiloride in the treatment of low renin hyperaldosteronism and related syndromes. Clin Sci Mol Med Suppl 45(Suppl 1):213s-218s
130. Wambach G, Helber A, Bonner G, Hummerich W, Meurer KA, Kaufmann W 1980 [Spironolactone in essential hypertension associated with abnormal aldosterone regulation and in Conn’s syndrome (author’s transl)]. Dtsch Med Wochenschr 105:647-651 (German)
131. Lim PO, Jung RT, MacDonald TM 1999 Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol 48:756-760
132. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, De Vries C, Plouin PF, Corvol P, Menard J 1987 Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60:820-825
133. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J 1987 Three new epoxy- spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 240:650-656
134. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S, Roniker B, Maurath C 2003 Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hyperten- sion. Clin Ther 25:2388-2404
135. Weinberger MH, Roniker B, Krause SL, Weiss RJ 2002 Eplerenone, a selec- tive aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15:709-716
136. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarc- tion. N Engl J Med 348:1309-1321
137. Lim PO, Young WF, MacDonald TM 2001 A review of the medical treatment of primary aldosteronism. J Hypertens 19:353-361
138. Farquharson CA, Struthers AD 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594-597
139. Farquharson CA, Struthers AD 2002 Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 88:475-480